According to the DataM market research report, the Global Inflammatory Bowel Disease Market size reached US$ 18,998.3 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 26,686.2 million by 2030. The global inflammatory bowel disease market is expected to exhibit a CAGR of 4.4% during the forecast period (2023-2030).
Treatment approaches for inflammatory bowel disease include medications (such as anti-inflammatory drugs, immunosuppressants, or biologic agents), lifestyle modifications, dietary changes, and, in some cases, surgery to remove or repair affected portions of the digestive tract. The global inflammatory bowel disease market is segmented on the basis of type, route of administration, drug class, distribution channel, and region.
North America is estimated to hold around 40.7% of the total market share throughout the forecast period, owing to the rising clinical trials and the increasing acquisition and collaborations among the market players. The major global players in the market include AbbVie Inc, Takeda Pharmaceutical Company Limited, Pfizer Inc, Biogen, Novartis AG, Eli Lilly Company, Merck & Co., Inc., Johnson & Johnson, Biocon Ltd., and Sanofi, among others.
In May 2023, Everest Medicines, a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative medicines and vaccines, announced the completion of patient enrollment in a multi-center Phase 3 clinical trial of etrasimod in Asia for the treatment of moderate-severe active ulcerative colitis (UC). The company will work closely with the regulatory authorities in Everest’s licensing territories and aim to file New Drug Application.
Biologic medications are commonly prescribed to manage moderate-to-severe inflammatory bowel disease (IBD), but they carry the potential for significant side effects. These side effects can include infections, an increased risk of lymphoma, and joint pain. Patients with IBD are more concerned about the risk of these side effects rather than the high costs associated with these medications.
Collaborations between pharmaceutical companies, biotech firms, academic institutions, and research organizations can accelerate the development of new therapies and diagnostic tools for IBD. Strategic partnerships that combine expertise and resources have the potential to bring novel innovations to market more efficiently.
For more details on this report – Request for Sample
Russia-Ukraine Conflict Analysis
The ongoing Russia-Ukraine conflict poses potential challenges for the IBS market. Supply chain disruptions may lead to medication shortages, impacting patient access to necessary treatments. Healthcare infrastructure in affected areas, including hospitals and clinics, may suffer damage and face service disruptions, affecting the diagnosis and management of IBS. The psychological toll of the conflict, such as stress and anxiety, can worsen IBS symptoms or trigger flare-ups in susceptible individuals.
Overall, the conflict’s impact on the IBS market encompasses medication availability, healthcare infrastructure, and psychological well-being. These factors suggest that the conflict has had a notable influence on the market during the forecast period.
Recent Developments in the Industry:
- On March 16, 2022, AbbVie received FDA approval for its drug RINVOQ (upadacitinib) to treat adults with moderate to severe ulcerative colitis (U.C.) who have not responded well or cannot tolerate tumor necrosis factor (TNF) blockers. The approval marks RINVOQ’s first use in gastroenterology and is based on the results of three Phase 3 clinical studies that demonstrated its safety and effectiveness.
- On February 27, 2023, AbbVie presented further analyses on SKYRIZI (risankizumab) in Crohn’s disease (CD) and RINVOQ (upadacitinib) in ulcerative colitis (U.C.) as well as the investigational use of upadacitinib in CD at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO), to be held March 1-4 in Copenhagen, Denmark. AbbVie will present 24 abstracts, including four oral presentations, two digital oral presentations, and 18 posters from a broad range of studies across its inflammatory bowel disease (IBD) portfolio.
- On December 21, 2022, Pfizer Inc. shared that the U.S. Food and Drug Administration (FDA) has taken up the review of a New Drug Application (NDA) for etrasimod, which is intended for people who live with moderately to severely active ulcerative colitis (U.C.). The FDA is expected to announce its decision in the second half of 2023. Additionally, the European Medicines Agency (EMA) has received the Marketing Authorization Application (MAA) for etrasimod for the same patient population, and the decision is expected in the first half of 2024.
As per the research analysis, the global inflammatory bowel disease market is segmented by type into Crohn’s disease and ulcerative colitis; by route of administration into oral route, rectal route, subcutaneous route, and intravenous route; by drug class into aminosalicylates, corticosteroids, TNF inhibitors, IL inhibitors, anti-integrin, JAK inhibitors, and others; by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies.
- Based on type, the ulcerative colitis segment accounted for the highest market stake, accounting for approximately 38.4% of the inflammatory bowel disease market in 2022. Ulcerative colitis primarily affects the colon and rectum, resulting in inflammation and ulcers in the inner lining of the large intestine. It is characterized by symptoms such as bloody diarrhea, abdominal pain, and urgency to have bowel movements.
The medication’s goal of treatment is to control inflammation, relieve symptoms, and promote healing of the affected areas. The specific drugs used to treat ulcerative colitis may vary depending on the severity of the condition and individual patient factors. The commonly used medications include aminosalicylates (5-ASAs) (mesalamine, sulfasalazine, and olsalazine), as these drugs are often the first-line treatment for mild to moderate ulcerative colitis.
The global inflammatory bowel disease market is segmented into North America, Europe, South America, Asia Pacific, and Middle East & Africa.
North America Inflammatory Bowel Disease Market:
North America is estimated to hold around 40.7% of the total market share throughout the forecast period, owing to the rising clinical trials, the increasing acquisition and collaborations among the market players, and increasing FDA approvals are the factors expected to boost the region’s growth over the forecast period.
For instance, on April 13, 2023, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter for the mirikizumab biologic license application (BLA) for the treatment of ulcerative colitis (UC). In the letter, the FDA cited issues related to the proposed manufacturing of mirikizumab, with no concerns about the clinical data package, safety, or label for the medicine.
The major global players in the market include AbbVie Inc, Takeda Pharmaceutical Company Limited, Pfizer Inc, Biogen, Novartis AG, Eli Lilly Company, Merck & Co., Inc., Johnson & Johnson, Biocon Ltd., and Sanofi, among others.
Suggestions for Related Report
For more Pharmaceutical related reports, please click here
Additional Benefits Post Purchase:
1) Unlimited Analyst support for a period of 1 year.
2) Any query with regard to the scope offered will be addressed within 24- 48 hours.
3) An Excel sheet with market numbers will be provided separately.
The Full Report has the below insights:
- The report offers a comprehensive evaluation of the market in terms of market value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2021-2022) and verifiable projections about market size during the forecast period (2023-2030).
- Visualize the composition of the global inflammatory bowel disease market by type, route of administration, drug class, distribution channel, and region, highlighting the key commercial assets and players.
- By Type: Crohn’s Disease, Ulcerative colitis
- By Route of Administration: Oral Route, Rectal Route, Subcutaneous Route, and Intravenous Route
- By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Others
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
- By Region: North America, South America, Europe, Asia Pacific, Middle East & Africa
- Identify commercial opportunities in the global inflammatory bowel disease market by analyzing trends and co-development deals.
- The report also covers data insights on various industry forces such as Porter’s five forces analysis, supply chain analysis, pricing analysis, regulatory analysis.
- Excel data sheet with thousands of data points of global inflammatory bowel disease market-level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in Excel for the key product of all major market players
The report will provide access to approximately 61 market data tables, 64 figures and close to 180 pages.
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you.
We encompass a multitude of Syndicate Reports & Customized Reports with a robust methodology. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.